One hundred forty-seven consecutive patients with leukemia, myelodysplastic syndrome, or aplastic anemia were treated by marrow grafts from genotypically HLA-identical siblings (n = 122) or HLA-haploidentical family members (n = 25). Haploidentical recipients differed from their donors for no more than one HLA locus on the nonshared haplotype. All were given postgrafting immunosuppression with a combination of methotrexate and cyclosporine. In a randomized study we explored whether prednisone administered from day 0 through 35 along with methotrexate/ cyclosporine could improve prevention of acute graftversus-host disease (GVHD). The GVHD incidence in patients not given prednisone was comparable with that previously reported with methotrexate/cyclosporine. Unexpectedly, significant increases in acute and also chronic GVHD were seen in HLA-identical recipients administered prednisone, but not in the small number of patients administered HLA-nonidentical grafts. However, the resultant increase in transplant-related mortality in patients administered prednisone was offset by an increase in WO PROSPECTIVE randomized trials in patients with T leukemia or aplastic anemia have shown a combination of methotrexate/cyclosporine to be superior to either drug alone in preventing acute graft-versus-host disease (GVHD) and improving overall survival.',* Despite this improvement, approximately 20% to 30% of HLA-identical marrow graft recipients administered methotrexate/cyclosporine still develop significant acute GVHD, a complication that carries a high risk of death. Prednisone has been shown to be effective in the treatment of established acute GVHD.3,4 Also, at least three transplant teams have used prednisone in addition to cyclosporine, methotrexate, or cyclophosphamide in a nonrandomized fashion to prevent GVHD.5-7 Therefore, we sought to determine if addition of prednisone to the methotrexate/ cyclosporine schedule would further reduce the incidence of acute GVHD. The study was performed in patients administered either genotypically HLA-identical or haploidentical marrow grafts for the treatment of acute nonlymphoblastic leukemia (ANL). chronic myelocytic leukemia (CML), preleukemia, or aplastic anemia. Haploidentical recipients differed from their donors for no more than one HLA-locus on the nonshared haplotype. All patients were administered methotrexate/cyclosporine, and then were randomized to receive or not to receive additional prednisone during the first 35 days after transplantation. Unexpectedly, results showed significant increases in acute and chronic GVHD in patients given added prednisone. March 18, 1986 to September 10, 1987 consecutive patients were entered in the study. Although a total accrual of 340 patients had been planned, the study was terminated early on the basis of results from an interim analysis. Characteristics of the patients are shown in Table 1 . The protocol and consent forms were leukemic relapse in patients not administered prednisone, presumably related t o the absence of a graft-versusleukemia effect. Therefore, overall disease-free survival of the t w o groups of patients was comparable, with slightly more than 50% of the patients being alive at more than 2 years after transplantation. We speculated that prednisone adversely affected GVHD prophylaxis, interfering with methotrexate's cell cycle-dependent suppression of donor lymphocyte proliferation in response t o host antigens. In a pilot study we explored whether beginning prednisone on day 15, after completion of methotrexate administration, would avoid this adverse effect. The GVHD incidence in patients administered methotrexate/cyclosporine along with "late" prednisone was comparable with that in patients not administered prednisone. We conclude that methotrexate/cyclosporine is effective in decreasing the incidence of grade II through IV GVHD, and that the addition of prednisone t o this regimen is not beneficial in recipients of HLA-identical marrow grafts.
One hundred forty-seven consecutive patients with leukemia, myelodysplastic syndrome, or aplastic anemia were treated by marrow grafts from genotypically HLA-identical siblings (n = 122) or HLA-haploidentical family members (n = 25). Haploidentical recipients differed from their donors for no more than one HLA locus on the nonshared haplotype. All were given postgrafting immunosuppression with a combination of methotrexate and cyclosporine. In a randomized study we explored whether prednisone administered from day 0 through 35 along with methotrexate/ cyclosporine could improve prevention of acute graftversus-host disease (GVHD). The GVHD incidence in patients not given prednisone was comparable with that previously reported with methotrexate/cyclosporine. Unexpectedly, significant increases in acute and also chronic GVHD were seen in HLA-identical recipients administered prednisone, but not in the small number of patients administered HLA-nonidentical grafts. However, the resultant increase in transplant-related mortality in patients administered prednisone was offset by an increase in WO PROSPECTIVE randomized trials in patients with T leukemia or aplastic anemia have shown a combination of methotrexate/cyclosporine to be superior to either drug alone in preventing acute graft-versus-host disease (GVHD) and improving overall survival.',* Despite this improvement, approximately 20% to 30% of HLA-identical marrow graft recipients administered methotrexate/cyclosporine still develop significant acute GVHD, a complication that carries a high risk of death. Prednisone has been shown to be effective in the treatment of established acute GVHD.3,4 Also, at least three transplant teams have used prednisone in addition to cyclosporine, methotrexate, or cyclophosphamide in a nonrandomized fashion to prevent GVHD.5-7 Therefore, we sought to determine if addition of prednisone to the methotrexate/ cyclosporine schedule would further reduce the incidence of acute GVHD. The study was performed in patients administered either genotypically HLA-identical or haploidentical marrow grafts for the treatment of acute nonlymphoblastic leukemia (ANL). chronic myelocytic leukemia (CML), preleukemia, or aplastic anemia. Haploidentical recipients differed from their donors for no more than one HLA-locus on the nonshared haplotype. All patients were administered methotrexate/cyclosporine, and then were randomized to receive or not to receive additional prednisone during the first 35 days after transplantation. Unexpectedly, results showed significant increases in acute and chronic GVHD in patients given added prednisone.
MATERIALS AND METHODS
From March 18, 1986 to September 10, 1987, 147 consecutive patients were entered in the study. Although a total accrual of 340 patients had been planned, the study was terminated early on the basis of results from an interim analysis. Characteristics of the patients are shown in Table 1 . The protocol and consent forms were leukemic relapse in patients not administered prednisone, presumably related t o the absence of a graft-versusleukemia effect. Therefore, overall disease-free survival of the t w o groups of patients was comparable, with slightly more than 50% of the patients being alive at more than 2 years after transplantation. We speculated that prednisone adversely affected GVHD prophylaxis, interfering with methotrexate's cell cycle-dependent suppression of donor lymphocyte proliferation in response t o host antigens. In a pilot study we explored whether beginning prednisone on day 15, after completion of methotrexate administration, would avoid this adverse effect. The GVHD incidence in patients administered methotrexate/cyclosporine along with "late" prednisone was comparable with that in patients not administered prednisone. We conclude that methotrexate/cyclosporine is effective in decreasing the incidence of grade II through IV GVHD, and that the addition of prednisone t o this regimen is not beneficial in recipients of HLA-identical marrow grafts. Before marrow transplantation, patients with acute or chronic myelogenous leukemia received intravenous (IV) cyclophosphamide (60 mg/kg of body weight) on each of 2 successive days, except in one case where etoposide was substituted for cyclophosphamide. In 59 patients this was followed by 2 Gy of total body irradiation on each of 6 successive days, and in 61 patients by 2.25 Gy of total body irradiation on each of 7 successive days (Table  The radiation was delivered by two opposing cobalt 60 sources at a rate of 6.5 cGy/min. The 14 patients with myelodysplastic syndrome all received cyclophosphamide followed by 2 Gy of total body irradiation on each of 6 successive days." The 13 patients with aplastic anemia received IV cyclophosphamide, 50 mg/kg body weight, on each of 4 successive days.' Within 4 hours of the last dose of total body irradiation, or 36 hours after the last dose of cyclophosphamide, donor marrow was infused IV. The day of marrow infusion was designated as day 0.
Postgrafting immunosuppression in all patients consisted of meth-otrexate/cyclosporine.'.* Methotrexate was administered at a dose of 15 mg/m2 of body surface area IV on day 1 and 10 mg/m2 on days 3, 6, and 1 1 after grafting. Cyclosporine was begun on the day before transplantation and was administered IV at a dose of 1.5 mg/kg every 12 hours until the patient recovered from conditioning regimeninduced gastrointestinal toxicity. Thereafter, the patients received 6.25 mg/kg of oral cyclosporine every 12 hours. The full dose of cyclosporine was administered until day 60 unless nephrotoxicity developed; if the serum creatinine doubled above baseline values, the dose was reduced by 50%; the drug was not administered at all if the creatinine exceeded 2 mg/dL (177 pmol/L). After day 60 the cyclosporine dose was decreased by 5% per week. In those patients who did not have acute GVHD or whose acute GVHD had resolved, a second randomization took place on day 60, designed to test whether tapering cyclosporine had any advantages over stopping abruptly. Thus, 36 patients were randomized to stop cyclosporine and 37 were randomized to continue with 5% decrements per week until day 180 after transplantation. This second phase of the study, which also included patients from other acute GVHD prophylaxis protocols, has not been finally analyzed. However, initial results suggest no significant differences in the incidence of chronic GVHD or of survival. Because the purpose of the current study was to prevent acute GVHD, final results of the second randomization will not be described here, although the effect of the second randomization has been entered as a covariate in the multivariate regression analysis on chronic GVHD presented (see Table 4 ). Seventy-three patients in the current study were randomized to receive methylprednisolone (referred to as "prednisone" throughout), and 74 were randomized not to receive prednisone. Characteristics of the patients are shown in Table 1 . Prednisone was begun on the day of marrow grafting at a dose of 1 mg/kg IV in divided AM and PM doses through day 22. From day 22 through day 35, prednisone was administered IV at a dose of 0.5 mg/kg in divided doses and then discontinued.
Of the 147 patients in the current protocol, 94 were enrolled in a protocol evaluating the effect of prophylactic IV immunoglobulin (Ig) in preventing infections after marrow transplantation. Fortyfour of the 94 patients were randomized to receive IV Ig as shown in Table 1 . Because IV Ig was found to have a beneficial effect on acute GVHD, this variable was entered as a cofactor in the logistic regression analyses (see Tables 3 and 4) . IV Ig (Gamimune N; Sandoz Pharmaceuticals Corp, East Hanover, NJ) was administered at a dose of 500 mg/kg of body weight weekly from days -7 to 90 after transplantation, and then monthly to day 360."
After terminating entry onto the randomized trial, an additional 24 HLA-identical patients were administered prednisone later, beginning on day 15 after transplantation (see Table 5 for their characteristics). They were administered methotrexate and cyclosporine as described. In addition, they received methylprednisolone starting on day 15 at 1 mg/kg/d IV for 1 week, then decreased to 0.5 mg/kg/d IV on day 22 and continuing through day 35.
Histocompatibility typing of donors and recipients was performed as previously described." Assessment, grading, and treatment of acute and chronic GVHD have been previously reported." Documentation of hematopoietic engraftment was based on blood counts and routine marrow aspirates, along with cytogenetic studies or restriction enzyme fragment length polymorphism studies, which were usually performed on days 14,21, 56, 84, and 365 after transplantation.
This study was designed to detect a 17% reduction in the incidence of acute GVHD with a maximum enrollment of 340 patients. Consecutive patients were randomized to receive or not to receive prednisone using a permuted block randomization schemeI3 within strata defined by combinations of the factors, diagnosis, patient age (less than 25 years v greater than 25 years), HLA match, and assignment to laminar airflow room. An interim analysis in July 1987, when results were available for 82 patients, indicated that the incidence of acute GVHD was, in fact, higher in the prednisone arm (P = .06, logrank test). Moreover, the probability of observing a statistically significant positive result at the planned completion of the study was only 9% given the interim results and the optimistic assumption that prednisone might actually decrease the incidence of acute GVHD by as much as 10%. Therefore, it was decided to terminate the randomized trial in September 1987 after enrolling 147 patients.
The primary factor analyzed was incidence of acute GVHD. Cumulative incidence curves were calculated with deaths from other causes treated as competing risks.I4 Differences between the groups were tested using a Pearson chi-squared statistic rather than a logrank statistic. This was done because the Pearson chi-squared statistic does not depend on the validity of the proportional hazards assumption and because follow-up was similar in the two groups. We used a logistic regression model to perform a multivariate analysis of the risk of acute GVHD adjusting for patient age, isolation in laminar airflow room, IV Ig administration, and patient and donor sex parity, all of which are suspected of being associated with the risk For personal use only. on September 14, 2017. by guest www.bloodjournal.org From of acute GVHD in HLA-identical marrow recipients. There was some imbalance in patient age, IV Ig administration, patient sex, and donor sex-parity between the two study arms, and this analysis allowed for inference regarding the acute GVHD prophylaxis despite this imbalance.
The cumulative incidence of relapse was calculated by treating deaths from other causes as competing risks. Only patients who survived 100 days posttransplant were included in the analyses of chronic GVHD. We used Pearson chi-squared statistics and a logistic regression analysis to analyze the influence of prednisone on the risk of developing chronic GVHD. The possible confounding influences of patient age and the day 60 randomization to discontinue cyclosporine were controlled for in the multivariate analysis. We also plotted an estimate of the prevalence of chronic GVHD among surviving disease-free patients as a function of time posttransplant in the two groups.I5 These curves acknowledge that some patients recover from chronic GVHD. Test statistics to compare these curves were calculated as described.I6
Standard survival analysis methods (Kaplan-Meier curves, logrank statistics, Cox regression models) were used to analyze survival and disease-free survival.
All tests were two-sided. The results presented here include our findings as of July 20, 1989.
RESULTS
The posttransplantation results are summarized in Table  2 .
Engraftment and early toxicity. One hundred thirtyseven of the 147 patients had sustained hematopoietic engraftment. Of the remaining 10 patients, seven died before day 19, too early to evaluate the fate of the graft. One who was HLA-nonidentical with the donor rejected the graft on day 80, and two who died on days 32 and 42 with hemorrhage and acute GVHD, respectively, had only poorly functioning grafts with granulocyte counts less than l,000/mm3. The recovery of granulocyte counts to l,000/mm3 was faster by 5 days in patients administered prednisone, possibly the result of demargination (P = .001, Table 2 ), whereas there were no statistically significant differences between the two groups in the time to discontinuation of transfusions of platelets and red blood cells (data not shown).
The degree of oral mucositis was comparable in the two groups of patients. Patients not administered prednisone had significantly higher bilirubin levels during the first 20 days after grafting (P = .02). Approximately one third of the patients in both groups showed doubling of creatinine over baseline or creatinine over 2 mg/dL, although there was a slightly higher incidence of need for dialysis in patients not administered prednisone. The incidence of hypertension was comparable in both groups. Compliance with the methotrexate and cyclosporine regimen was similar in the two groups, although there was a trend for somewhat lower doses of both drugs to be administered in patients not receiving prednisone. The median serum levels of cyclosporine for weeks 1 through 5 after transplantation were comparable, although patients not administered prednisone had lower levels during weeks 4 and 5 ( Table 2) .
Finally, there was no significant difference between the two groups in the number of days spent in the hospital (median 63 v 57 days).
The cumulative incidence of acute grade Acute GVHD.
I1 through IV GVHD in HLA-identical and HLA-nonidentical patients combined is shown in the top part of Fig 1. Thirty-six percent of patients not administered prednisone had acute GVHD compared with 45% of patients administered prednisone (P = .28, Pearson chi-squared test). The onset of acute GVHD appeared earlier in patients not administered prednisone, with most disease developing before day 40. Fewer patients in the nonprednisone arm of the study developed grade IV acute GVHD (P = .13, Fisher's exact test). Among HLA-identical patients, these figures were 25% versus 46% (P = .02, Pearson chi-squared) (Fig   1) . All 11 HLA-nonidentical patients not administered prednisone and 6 of 12 patients administered prednisone developed acute GVHD (P = .01, Fisher's exact test).
A multivariate logistic regression analysis of the data for HLA-identical transplants, including as covariates donor sex and parity, patient sex, isolation in laminar airflow room, IV Ig administration, and patient age confirmed that patients not administered prednisone had significantly less acute GVHD than those administered prednisone (P = .OS, Table   3 ).
One hundred thirteen patients survived 100 days posttransplant and hence were a t risk for chronic GVHD. Of the 53 patients who received prednisone, 33 (62%) developed chronic GVHD whereas only 24 of the 60 patients (40%) who did not receive prednisone developed chronic GVHD (P = .01, Pearson chi-squared test). Even among those who had no prior acute GVHD (grade 0), 13 of 26 (50%) who received prednisone and 7 of 30 (23%) who did not receive prednisone developed chronic GVHD (P = .04). For patients with grade I through IV acute GVHD, corresponding numbers were 78% and 57% (P = .09), respectively. Figure 2 displays the prevalence of chronic GVHD among patients free of leukemic relapse. Chronic GVHD is a more significant problem among disease-free surviving patients who received prednisone than amongst those who did not receive prednisone (P = .02).
We performed a multivariate logistic regression analysis that adjusted for preceding acute GVHD, patient age, IV Ig administration, and randomization to discontinue CSP on day 60 or day 180. This analysis confirmed that the association between prednisone and increased risk of chronic GVHD was independent of any other associations (P = .02. Table   Amongst haploidentical recipients who survived 100 days posttransplant, 4 of 9 in the prednisone arm developed chronic GVHD and 6 of 10 in the nonprednisone arm developed chronic GVHD.
Leukemic recurrence. Leukemic recurrence was seen in patients with ANL in remission or in relapse and in patients with CML. More relapses were seen among patients not administered prophylactic prednisone (28% cumulative incidence) than in patients administered prophylactic prednisone (14% cumulative incidence) (P = .07 Pearson chi-squared statistic). Figure 3 shows the findings separately for ANL and C M L patients. Overall, A N L patients had a higher incidence of leukemic recurrence with 23% of the prednisonetreated and 42% of the nonprednisone-treated patients develChronic GVHD.
4).
For personal use only. IlDefined as diastolic 290 mm hg on at least two separate daily measurements. YCalculated on the basis of data in patients while they were alive and without acute GVHD during the first 5 weeks posttransplant.
#Cyclosporine levels were determined according to a previously published method. " *Hemorrhage, cerebrovascular accident, other malignant tumor.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From who relapsed died from that complication. Eight patients died from complications associated with chronic GVHD or its treatment, predominantly gram-positive infections.
One possible explanation for the observed higher incidence of acute GVHD among patients administered prednisone from day 0 through 35 is that the drug interfered with the initial proliferation of alloantigen-activated lymphocytes and thereby reduced the action of the antimetabolite methotrexate. For this reason, we explored whether starting prednisone later, 15 days after transplantation and 4 days after the last dose of methotrexate, would reduce the incidence of acute GVHD. Twenty-four recipients of marrow from HLA-identical siblings, whose characteristics are shown in Table 5 , were entered onto this arm of the study. Figure 5 suggests that the cumulative incidence of acute GVHD among these patients was different from that seen in the 59 HLA-identical recipients administered "early" prednisone beginning on day 0 (P = .08, Pearson chi-squared test). Indeed, the cumulative incidence of acute GVHD in the late prednisone group was similar to that among HLAidentical recipients who did not receive prednisone. Patients administered late prednisone had no grade IV acute GVHD.
Patients administered "late" prednisone.
-loo[ All Recipients oping relapse, compared with 4% of prednisone-treated CML patients and 14% of nonprednisone-treated C M L patients. Projected survival at 2 years was 53% among the patients who received prednisone, as compared with 54% among the patients who did not receive prednisone (not shown). Differences between the two study groups were not significant ( P = .95). Similarly, relapse-free survival was not different in the two groups ( P = .85), with the projected values at 2 years posttransplant being 51% in both groups (Fig 4) . Overall, any advantages for patients not administered prednisone from the lower incidence of death associated with GVHD was offset by a higher rate of leukemic relapse seen in particular among patients with ANL. Twoyear survival for patients with A N L was 55% for those administered prednisone and 34% for those not administered prednisone (P = .095); the figures for patients with CML were 52% 2-year survival for those administered prednisone and 77% for those not administered prednisone ( P = .06).
Eight patients administered prednisone and seven not administered prednisone died within the first 100 days from causes not related to GVHD. Twelve patients administered prednisone and 7 not administered prednisone died from GVHD-related causes. Fungal and bacterial infections and pneumonia associated with cytomegalovirus, idiopathic interstitial pneumonia, and respiratory failure due to these disorders were the leading causes of death ( Table 2) . Recurrent leukemia was observed in nine patients in the group administered prednisone and 17 in the group not administered prednisone. 'The odds is: (probability of GVHD/probability of no GVHD). The log odds ratio at a particular value of the factor is the logarithm of the ratio of the odds among those with that value of the factor relative to the odds at the baseline value of the factor. t l V Ig, intravenous immunoglobulin. $There were less than 10 patients in some categories of these factors. However, the coefficients and P values for all other factors remained virtually unchanged when patient sex and donor parity were removed from the model. Projected survival for this group of patients is 63% at 1 year posttransplant. The cumulative incidence of chronic GVHD among 100 day survivors is 55%. DISCUSSION Previous studies in patients undergoing HLA-identical marrow transplantation for the treatment of leukemia and aplastic anemia have shown the combination of methotrexate and cyclosporine to be superior to either drug alone with regard to reducing the incidence and severity of acute GVHD.'.' Yet, despite the efficacy of the combination, between 20% and 30% of patients so treated continue to show moderately severe acute GVHD. Results for those patients in the current study who were administered the combination of methotrexate and cyclosporine alone corroborate the previous data, and 26% of the HLA-identical recipients developed grade I1 through IV acute GVHD.
Acute GVHD in methotrexate/cyclosporine-treated patients is generally diagnosed within the first 35 days of transplantation. It tends to respond to treatment with predni~one.'.~ For this reason we explored the usefulness of prophylactic prednisone administered for the first 35 days after transplantation in improving prevention of acute GVHD. Results were disappointing, and a significant increase in the .41
Only three HLA-nonidentical patients survived to day 100 without 'The odds ratio was defined in Table 3 . t l V lg, intravenous immunoglobulin.
acute GVHD. None of these developed chronic GHVD. Years after Marrow Graft For personal use only. on September 14, 2017. by guest www.bloodjournal.org From incidence of acute GVHD was seen with more patients having grade IV disease. Of interest, the increase was restricted to recipients of HLA-identical sibling transplants. Recipients of one HLA-locus mismatched marrow grafts who were administered prednisone had a lower incidence of acute GVHD than their nonprednisone-treated counterparts. The significance of this finding is tempered by the fact that only a small number of HLA-nonidentical patients was studied. Not only did patients administered HLA-identical marrow grafts and additional prednisone show an increase in the incidence of acute GVHD, they also experienced significantly more chronic GVHD. This adverse effect of prednisone on chronic GVHD could not be explained solely on the basis of the direct relationship between acute and chronic GVHD since it was also seen in patients without preceding acute GVHD. One explanation for the adverse effect of prophylactic prednisone on acute GVHD in HLA-identical recipients is the possibility that it interfered with tolerance induction achieved by methotrexate administered early after transplantation. The antimetabolite is thought to affect those donor For personal use only. on September 14, 2017. by guest www.bloodjournal.org From lymphocytes that have proliferated in response to host alloantigens. It is conceivable that prednisone prevented the events leading to lymphocyte replication. Hence methotrexate, while causing toxicity, was ineffective in preventing acute GVHD. Results of an attempt to test this hypothesis by beginning prednisone later, on day 15 after transplantation, were consistent with this explanation. The incidence of acute GVHD in the 24 HLA-identical recipients administered "late" prednisone was less than that in patients administered early prednisone and similar to that in HLA identical recipients who did not receive prednisone, suggesting that prednisone administered in this fashion was neither harmful nor beneficial with regard to acute GVHD.
Another possibility is that prednisone acts to eliminate or inactivate host lymphoid cells that survived the conditioning program and may be involved in down-regulating graft-versushost responses. This speculation is based on observations in experimental ani mal^'^.'^ and in patients" documenting a reduced GVHD incidence in recipients who show mixed donor and recipient hematopoietic chimerism. Host lymphoid cells, possibly pre-T cells, in these mixed chimeras are thought to be important in avoiding GVHD, and they might have been eliminated by prednisone therapy. Circumstantial evidence in support of this speculation is also provided by the observation of a significant increase in chronic GVHD in those patients transplanted for aplastic anemia who had extended steroid therapy before transplantation.21 An argument against the possibility of prednisone affecting the surviving host lymphoid population is that mixed chimerism measured by conventional cytogenetic studies is exceedingly rare in this transplant setting for patients with hematologic malignancy. However, more recent studies using restriction fragment length polymorphism or y-chromosome specific in situ hybridization showed that small numbers of host cells may persist for some time.22.23
Whether the current findings have implications for other GVHD prevention protocols in which cyclosporine, methotrexate, or cyclophosphamide are combined with prednisone5-' is conjectural. Generally, these studies did not evaluate in a prospective fashion whether the addition of prednisone was beneficial, of no influence, or had adverse effects. Moreover, in most of these reported trials prednisone was not administered before day 8 and it was administered for longer periods. In this context it is interesting that in the present study approximately half of the cases with GVHD were diagnosed after day 35, when prednisone had been discontinued. Our study indicates the need for randomized studies of the role of prednisone in the other regimens.
Despite a higher incidence of transplantation-related mortality, largely due to GVHD, the relapse-free survival of the two groups of patients in the present study was comparable with slightly more than 50% of the patients in both groups being alive disease-free at more than 2 years after transplantation. This is largely explained by a lower relapse rate among prednisone-treated patients, which in part may reflect a graft-versus-host anti-leukemic e f f e~t~~.~~ or a direct effect of prednisone on leukemic recurrence. The problem of relapse was greater in patients with ANL than in those with CML. Nonprednisone-treated patients with CML had a disease-free long-term survival of 75%, consistent with previously reported finding^.'.^'
We conclude from this study that methotrexate/cyclosporine is effective in decreasing the incidence of grade I1 through IV GVHD, confirming previous observations. The addition of prednisone to this regimen had the paradoxical effect of increasing the incidence of acute and chronic CVHD, thereby increasing transplantation-related mortality. Thus, the prophylactic use of this drug in this setting was not beneficial.
